Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > BioSante Pharmaceuticals Announces Positive Results

Abstract:
BioSante Pharmaceuticals, Inc. (Amex: BPA) today announced positive results of the use of BioSante's calcium phosphate nanotechnology (CaP) as a potential wrinkle filler in cosmetic medicine. These results are based on work performed by Medical Aesthetics Technology Corporation ("MATC") with whom BioSante has entered into an exclusive option and license agreement in the field of aesthetic medicine. Pre-clinical work to date indicates that BioSante's CaP nanotechnology performs well as a filler and may be as long lasting and safe as other injectable fillers. Preliminary results indicate long lasting effects and no adverse events. Further pre-clinical tests are being conducted to confirm the positive results and determine whether BioSante's CaP can extend the beneficial wrinkle-filling effects longer than those produced by the leading hyaluronic acid fillers, such as Restylane made by Medicis Pharmaceutical Corp. (NYSE:MRX), which typically last about six months after injection into the skin. Human clinical testing of CaP for this use is being planned.

BioSante Pharmaceuticals Announces Positive Results

LINCOLNSHIRE, IL | Posted on July 25th, 2007

Stephen M. Simes, BioSante's president and chief executive officer, stated, "The area of aesthetic medicine is growing both in prescription and non-prescription products. Results to date are indicative that CaP may have a role to play in aesthetic medicine in a large and growing market. Our option and license agreement with MATC and the work in aesthetic medicine are part of our strategic effort to maximize the value of CaP to our stockholders."

BioSante and MATC have agreed to extend by four months the previous exclusive option period that would have expired in July 2007. MATC has the exclusive right to exercise an option to secure a license to this technology in the field of aesthetic medicine upon payment to BioSante of a license fee. BioSante has the right to receive additional milestone payments upon approval by the U.S. Food and Drug Administration (FDA) or first commercial sale of each product containing CaP, a royalty on net sales of any such products, and a share of any milestones and license fees from third party sublicenses.

####

About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine. Additional information is available online at http://www.biosantepharma.com .

About Medical Aesthetic Technologies Corporation

Medical Aesthetic Technologies is engaged in research and development to produce novel products in the field of aesthetic medicine. MATC has assembled a team of accomplished professionals out of Harvard and MIT with expertise in aesthetic medicine as well as technology development.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this news release that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “would,” “likely,” “expects,” “anticipates,” “estimates,” “believes,” “plans,” “hopes,” or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to BioSante that could cause actual results to differ materially from those expressed in such forward-looking statements include the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, the success of clinical testing, and other factors identified and discussed from time to time in BioSante's filings with the Securities and Exchange Commission, including those factors discussed in BioSante's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which discussions also are incorporated herein by reference. All forward-looking statements speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please click here

Contacts:
BioSante Pharmaceuticals, Inc.
Phillip Donenberg
(847) 478-0500

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Researchers create vaccine for dust-mite allergies Main Page Content: Vaccine reduced lung inflammation to allergens in lab and animal tests July 22nd, 2014

NIST shows ultrasonically propelled nanorods spin dizzyingly fast July 22nd, 2014

SentiMag® Now Available in Australia and New Zealand July 21st, 2014

More than glitter: Scientists explain how gold nanoparticles easily penetrate cells, making them useful for delivering drugs July 21st, 2014

Announcements

Harris & Harris Group to Host Conference Call on Second-Quarter 2014 Financial Results on August 15, 2014 July 23rd, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Deadline Announced for Registration in 7th Int'l Nanotechnology Festival in Iran July 23rd, 2014

A Crystal Wedding in the Nanocosmos July 23rd, 2014

Personal Care

Nanotechnology used in sunscreens: a Mexican achievement May 14th, 2014

Production of Nanocapsule from Sea-Buckthorn Extract in Iran May 3rd, 2014

Good vibrations: Using light-heated water to deliver drugs - Researchers use near-infrared light to warm water-infused polymeric particles April 1st, 2014

Iranian Food Industry Utilizes Lipid Nanocarriers for Beta-Carotene Enrichment January 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE